Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory ...

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at hmpgloballearningnetwork.com →

◆ Verified

Fusion42 · 13 August 2026 · Fusion42 review

The FDA has granted accelerated approval to a combination therapy including iberdomide for patients with relapsed or refractory multiple myeloma, providing a new treatment option for this difficult-to-treat cancer.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

Accelerated FDA approval has shortened the path to market for oncology drugs involving iberdomide. Founders in multiple myeloma therapeutics must act now to adjust regulatory and clinical plans to capitalise on this faster approval route.

◆ Coverage

3 sources · 13 Aug 2026

◆ Related on Wire

◆ Topics

BiotechFDAaccelerated-approvalmultiple-myelomaiberdomideoncologydrug-approval